|Title:||Global laboratory equipment companies listed alphabetically with currency neutral sales per employee, number of employees, and percent change for 2011|
|Source:||Instrument Business Outlook|
Start of full article - but without data
Company Curr. Neu. Empl. Sales per #of Chg. Employee Employees 2010-XX
Affymetrix $XXX,XXX XXX -X.X% Analytik Jena $XXX,XXX XXX X.X% (Analy. Inst., LifeSci.) Blotage AB $XXX,XXX XXX -X.X% Bruker (BSI) $XXX,XXX X,XXX XX.X% Eppendorf $XXX,XXX X,XXX -X.X% FEI $XXX,XXX X,XXX XX.X% Fluidigm $XXX,XXX XXX XX.X% Harvard Bioscience $XXX,XXX XXX X.X% Illumina $XXX,XXX X,XXX X.X% Life Technologies $XXX,XXX XX,XXX -X.X% Luminex $XXX,XXX XXX XX.X% Oxford Instruments $XXX,XXX X,XXX XX.X% PerkinElmer $XXX,XXX X,XXX XX.X% QIAGEN $XXX,XXX X,XXX X.X% Sequenom $XXX,XXX XXX XX.X% Sigma-Aldrich $XXX,XXX X,XXX X.X% Tecan $XXX,XXX X,XXX X.X% Thermo Fisher Scientific $XXX,XXX XX,XXX X.X% Waters $XXX,XXX X,XXX X.X%
Company Curr. Neu. Produc- Rev. Chg. tivity Chg. 2009-XX 2010-XX
Affymetrix -XX.X% -XX.X% Analytik Jena X.X% X.X% (Analy. Inst., LifeSci.) Blotage AB X.X% X.X% Bruker (BSI) XX.X% X.X% Eppendorf X.X% X.X% FEI XX.X% XX.X% Fluidigm XX.X% XX.X% Harvard Bioscience -X.X% -X.X% Illumina XX.X% XX.X% Life Technologies X.X% XX.X% Luminex XX.X% XX.X% Oxford Instruments XX.X% X.X% PerkinElmer XX.X% -X.X% QIAGEN X.X% -X.X% Sequenom XX.X% -XX.X% Sigma-Aldrich X.X% X.X% Tecan XX.X% X.X% Thermo Fisher Scientific X.X% X.X% Waters X.X% X.X%
In fiscal 2011 (FYXX), productivity growth for XX major publicly held lab instrument and product companies (see table, page X) slowed to X.X%, compared with X.X% in fiscal 2010. The slower growth, as measured by average sales per employee, was due to a jump in employment as a result of acquisitions and investments in emerging markets. For the XX firms, the total number of employees increased X.X% in FYXX, compared with X.X% in FYXX. However, acquisitions, along with higher demand in developing nations and product introductions, also elevated revenue growth. For the same companies, currency-neutral sales climbed X.X% in US dollars in FYXX, compared with X.X% growth in FYXX.
Despite the slower productivity growth, the average sales per employee improved to $XXX,XXX in FYXX from $XXX,XXX in FYXX, with XX of the XX companies reporting higher productivity Productivity growth was also driven by the strong revenue growth, including acquisitions and restructuring efforts that reduced R&D, manufacturing and sales personnel in developed regions.
IBO's calculations are based on FYXX employment and currency-neutral sales figures in US dollars. Sales growth for international companies is calculated at FYXX exchange rates.
Uncertainty regarding academic and government funding for research in the US and Europe and slower life science revenue growth for a number of companies in the second half of 2011 triggered restructuring activities at Illumina, Life Technologies, Thermo Fisher Scientific, QIAGEN and Affymetrix.
Despite the negative impact of lower research funding, both Illumina and Life Technologies achieved double-digit productivity growth in FYXX as a result of restructuring activities and demand for next-generation sequencing products. Illumina increased productivity by XX.X% in FYXX and recorded the highest sales-to-employee ratio of $XXX,XXX among US firms in the table. Illumina has had the highest sales-to-employee ratio in IBO's productivity tables for the last three years. Following revenue declines in the second half of FYXX, the company initiated a restructuring plan in the fourth quarter 2011 to lower its workforce by roughly X%, or XXX employees, and consolidate excess facility space (see IBO XX/XX/XX}. Nonetheless, the company grew its head count by X.X% due to increased R&D and sales personnel designated for the MiSeq systems.
Life Technologies expanded its sales-per-employee ratio by XX.X% in FYXX due to restructuring efforts. The company closed six manufacturing facilities and consolidated several sales offices. The company achieved $XX million in cost savings during the second half of the year, which included an undisclosed number of layoffs. In FYXX, Life Technologies reduced its workforce by X.X%. A majority of the layoffs were in the US, as the company's workforce outside the US climbed XX% to X,XXX to make up XX% of the total. In emerging markets, Life Technologies bolstered resources to improve its distribution network and build up a direct sales force. The company also opened new distribution facilities (see IBO X/XX/XX,X/XX/XX). At the end of 2011, the company reported nearly XXX employees in the greater China area, which includes mainland China, Taiwan and Hong Kong.
Despite the acquisitions of Dionex (see IBO XX/XX/XX) and Phadia (see IBO X/XX/XX), which had approximately X,XXX and X,XXX employees in fiscal 2010, respectively, Thermo managed to increase productivity by X.X% in FYXX due to restructuring and operational improvements. The company also benefited from higher pricing, manufacturing efficiencies and expanded low-cost manufacturing in China, Mexico and Eastern Europe. FYXX revenues from low-cost manufacturing countries amounted to $XXX million, or XX% of sales. The company consolidated XX manufacturing facilities, saved $XX million due to process improvements and saved $XX million from global sourcing. Thermo's Laboratory Products and Services, Analytical Technologies and Specialty Diagnostics segments terminated XXX, XXX and XX employees, respectively. However, Thermo also made investments in emerging markets (see IBO X/XX/XX, X/XX/XX).
Unlike Illumina, Life Technologies and Thermo, both Affymetrix and QIAGEN recorded productivity declines in FYXX despite restructuring measures. Affymetrix's productivity fell XX.X% despite organizational changes and a X.X% decline in head count, largely due to a XX.X% decline in sales. The company cut its R&D staff by about XX% and closed its Oakmead facility in California. As part of the restructuring, Affymetrix realigned its operations into three business units.
QIAGEN's productivity fell X.X% in FYXX due to a sizable workforce increase and slower academic and pharmaceutical demand. Due to the slowdown, the company implemented restructuring initiatives in the fourth quarter 2011 to reduce its workforce by X%-XX% (see IBO XX/XX/XX). These activities are expected to generate $XX million in cost savings. Despite head count reductions, the firm's total number of employees grew by XXX people, or by XX% of its workforce, due to acquisitions (see IBO X/XX/XX, X/XX/XX) and expansion into emerging markets. The company purchased Cellestis, which had roughly XX employees. QIAGEN's sales staff grew by XXX employees to account for XX% of total head count. Production and marketing head count rose XX% and XX% to represent XX% and XX% of its workforce, respectively. Total head count grew by XXX workers. However, revenue growth increased only X.X% or X.X% organically.
Besides Illumina, FEI was the only other US company in the table to show currency-neutral sales per employee of more than $XXX,XXX. FEI also recorded the highest percentage change in productivity in FYXX among firms in the table, as its productivity jumped XX.X% to $XXX,XXX. The company reported XX.X% sales growth. FEI's total head count rose XX.X%, as the company boosted its R&D staff by XX% to XXX and its service personnel by XX% to XXX.
Similar to Thermo, productivity for Sigma-Aldrich, Bruker, Oxford Instruments and PerkinElmer was impacted by acquisitions. In FYXX, productivity for Bruker Scientific Instruments climbed X.X%. Sales increased XX.X%, including XX.X% growth from acquisitions (see IBO X/X/XX, X/XX/XX,X/XX/XX). Bruker's workforce grew by XXX people due to acquisitions and investments in emerging markets (see IBO X/XX/XX). Sigma-Aldrich's head count grew X.X% in FYXX, and included XXX employees from the purchase of Vetec Quimica Fina (see IBO X/XX/XX). However, sales grew at a faster pace, rising X.X%. As a result, productivity improved X.X%.
Oxford Instruments' sales for the fiscal year ending March XX grew XX.X% (see page XX), including XX.X% growth from acquisitions and strong organic sales. However, the company's workforce expanded by XXX employees, including XXX employees from acquisitions (see IBO X/XX/XX, XX/XX/XX). The increase was also attributed to a XX% increase in R&D. Forty-four percent of FY! X sales were from products developed or acquired in the last three years. In local currency, productivity rose X.X% to XXX,XXX [pounds sterling].
PerkinElmer recorded a X.X% decline in productivity in FYXX due to eight acquisitions (see IBO X/XX/XX,X/XX /XX, X/XX/XX,X/XX /XX, X/XX/XX), including Caliper Life Sciences (see IBO X/XX/XX), which had roughly $XXX million in revenues and XXX employees. In FYXX, the company added X,XXX employees to its workforce. To improve operating costs, PerkinElmer initiated restructuring plans in the second and fourth quarters 2011, resulting in the termination of XX and XXX employees, respectively. The company also transferred manufacturing of certain instrumentation product lines from Connecticut to Singapore and the UK.
Like Oxford Instalments, other European firms recorded productivity gains. Eppendorf and Analytik Jena boosted productivity by X.X% and X.X% to XXX,XXX [euro] and XXX,XXX [euro] in native currencies, respectively. Eppendorf reduced its workforce by XX employees due to the divestiture of non-core assets in North America. However, the company added jobs primarily in Asia for sales and marketing, but also in Europe. Biotage's productivity rose X.X% to SEK X,XXX,XXX in native currency. Tecan increased productivity by X.X% to CHF XXX,XXX in native currency. The company added resources for sales and marketing to establish a direct sales force in Asia and increased R&D personnel XX.X% to XXX. In FYXX, Tecan's currency-neutral sales climbed XX.X%.
Aside from Affymetrix, PerkinElmer and QIAGEN, two other companies showed productivity declines in FYI X. Among companies in the table, Sequenom experienced the largest productivity decline due to a XX.X% rise in its workforce, related to the launch of its noninvasive proprietary MaterniTXX test. Harvard Bioscience recorded a X.X% decline in productivity, as sales slipped X.X% on a currency-neutral basis, but it benefited from an acquisition (see IBO X/XX/XX) and restructuring at Coulbourn Instruments and Hoefer.
Company Curr. Neu. Empl. Sales per #of Chg. Employee Employees 2010-XX
Affymetrix $XXX,XXX XXX -X.X% Analytik Jena $XXX,XXX XXX X.X% (Analy. Inst., LifeSci.) Blotage AB $XXX,XXX XXX -X.X% Bruker (BSI) $XXX,XXX X,XXX XX.X% Eppendorf $XXX,XXX X,XXX -X.X% FEI $XXX,XXX X,XXX XX.X% Fluidigm $XXX,XXX XXX XX.X% Harvard Bioscience $XXX,XXX XXX X.X% Illumina $XXX,XXX X,XXX X.X% Life Technologies $XXX,XXX XX,XXX -X.X% Luminex $XXX,XXX XXX XX.X% Oxford Instruments $XXX,XXX X,XXX XX.X% PerkinElmer $XXX,XXX X,XXX XX.X% QIAGEN $XXX,XXX X,XXX X.X% ...